Eukaryotic translation initiation factor 3 subunit C (EIF3C)

Eukaryotic translation initiation factor 3 subunit C (EIF3C) is a core protein subunit of the eukaryotic translation initiation factor 3 (eIF3) complex, which is essential for the initiation phase of eukaryotic protein synthesis[1][2]. EIF3C is required for the recruitment of the 40S ribosomal subunit to mRNA, the stabilization of the pre-initiation complex, and the regulation of translation of specific mRNAs involved in cell proliferation, cycling, differentiation, and apoptosis[1][2][3]. It mediates interactions with other translation initiation factors (e.g., eIF1, eIF5), and depletion of EIF3C impairs cell growth and viability, especially in dividing cells[1][3][4]. Elevated or dysregulated EIF3C activity has been linked to the pathogenesis and growth of several cancers, making it an emerging target for therapeutic intervention and a potential biomarker for cancer prognosis[4]. No drugs are currently listed as directly targeting EIF3C, but its central role in translation makes it a subject of investigation in cancer biology and pharmacology.

Other names

EIF3CEIF3S8eIF3ceIF3-p110Eukaryotic translation initiation factor 3 subunit 8eIF3 p110EIF3CLCell migration-inducing protein 17eukaryotic translation initiation factor 3, subunit 8 (110kD)eukaryotic translation initiation factor 3, subunit 8, 110kDa

Inhibition or silencing of EIF3C leads to decreased cell proliferation and increased apoptosis, particularly in cancer cells, by dysregulating translation initiation and affecting the expression of genes involved in signaling, cell growth, and apoptosis[4].